Reduce the cost and time it takes to conduct psychedelic studies.

Designed for academic researchers, biotech, insurance, and regulatory governance.

Navigating R&D is expensive and slow. Participant recruitment can be difficult and traditional clinical softwares are not designed for the nuances of psychedelic studies.

Our Real World Data Explorer changes that.

Real World Data provides the evidence needed to inform efficient psychedelic studies. Aggregate, derivative population data covering mental health treatments and outcomes are presented in an analytics dashboard, allowing you to segment data in real-time.

Key benefits to using Maya in your research:

Harness the power of real world data.

Real world data provides evidence for clinical efficacy and generate signals to inform further controlled study. Real world practices can directly instruct clinical pathway design, reducing current trial-and-error approaches, and accelerating safe care delivery.

Decrease costs and time.

Real world psychedelic data provides the opportunity to observe treatment practices and outcomes at a dramatically reduced cost in time and money vs running controlled studies.

Increase access to qualified study participants.

By empowering individuals with insight and clarity in their own healing journey, we can activate a global ‘army’ of qualified citizen scientists who are willing to participate in psychedelic studies.

How it works

Advanced Protocol Builder.

Build your research protocol easily using Maya’s Protocol elements ranging from individual therapeutic interventions to content elements for education during preparation and integration stages.

Insights Dashboard.

View results and calculate cohort performance in real-time through Maya’s integrated Insights Dashboard.

Participant Experience Management.

Customize and manage all communications with participant through the Maya Companion App.

Psychedelic-Specific Common Data Model.

The Maya Insights dashboard offers an unparalleled opportunity for real time analysis and preliminary investigation. All data is structured in a consistent and universal 'common data model', allowing for retroactive meta analysis and cross-study comparison.

Build Protocols

Advanced Protocol Builder.

Build your research protocol easily using Maya’s Protocol elements ranging from individual therapeutic interventions to content elements for education during preparation and integration stages.

Gain Insights

Insights Dashboard.

View results and calculate cohort performance in real-time through Maya’s integrated Insights Dashboard.

Manage

Participant Experience Management.

Customize and manage all communications with participant through the Maya Companion App.

Create

Psychedelic-Specific Common Data Model.

The Maya Insights dashboard offers an unparalleled opportunity for real time analysis and preliminary investigation. All data is structured in a consistent and universal 'common data model', allowing for retroactive meta analysis and cross-study comparison.

Prev arrow line grey icon
Next arrow line grey icon

Reduce the cost and time it takes to conduct psychedelic studies.

Join the researcher community

Key Benefits

Check blue line icon

Analysis-ready datasets covering diverse populations

(Coming soon)

Check blue line icon

Enhanced compliance vs general registries

(Coming soon)

Check blue line icon

Faster, cheaper participant recruitment

(Coming soon)

Check blue line icon

Retained data ownership & embargoed publishing rights

(Coming soon)

Check blue line icon

Unified data modeling & analysis across recruitment sites

(Coming soon)

Check blue line icon

HIPAA-compliant & IRB-approved methodologies

(Coming soon)

Check blue line icon

Enhanced participant experience & outcomes

(Coming soon)

Check blue line icon

Co-opted press & publicity for studies

(Coming soon)

Check blue line icon

Significantly larger datasets vs controlled study

(Coming soon)

Check blue line icon

Improved compliance

(Coming soon)

Check blue line icon

Improved compliance

(Coming soon)

Read our last article

Read More

Listen our last podcast

Read More